Ningbo Menovo Pharmaceutical (603538.SH): Lurasidone Hydrochloride API Receives CDE Technical Approval

Stock News
04 Aug

Ningbo Menovo Pharmaceutical Co.,Ltd. (603538.SH) announced that its subsidiary, Anhui Menova Pharmaceutical Chemistry Co., Ltd. ("Anhui Menova"), has received the "Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notice" for lurasidone hydrochloride API, approved and issued by China's National Medical Products Administration. The drug indication is for the treatment of schizophrenia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10